NN Investment Partners Holdings N.V. acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,067 shares of the medical device company’s stock, valued at approximately $1,958,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Prudential Financial Inc. increased its stake in DexCom by 2.2% during the 4th quarter. Prudential Financial Inc. now owns 4,668 shares of the medical device company’s stock valued at $559,000 after buying an additional 100 shares during the period. Dimensional Fund Advisors LP increased its stake in DexCom by 2.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 164,763 shares of the medical device company’s stock valued at $19,738,000 after buying an additional 3,468 shares during the period. Stifel Financial Corp increased its stake in DexCom by 88.0% during the 4th quarter. Stifel Financial Corp now owns 3,614 shares of the medical device company’s stock valued at $435,000 after buying an additional 1,692 shares during the period. Geode Capital Management LLC increased its stake in DexCom by 17.2% during the 4th quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock valued at $124,776,000 after buying an additional 152,781 shares during the period. Finally, Stone Ridge Asset Management LLC acquired a new position in DexCom during the 4th quarter valued at about $225,000. Hedge funds and other institutional investors own 96.32% of the company’s stock.
Shares of DXCM traded down $1.47 during mid-day trading on Thursday, hitting $151.49. The company’s stock had a trading volume of 366,636 shares, compared to its average volume of 1,243,420. The company has a 50-day moving average of $146.16. The company has a market cap of $13.79 billion, a PE ratio of 504.97 and a beta of 0.82. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75. DexCom, Inc. has a fifty-two week low of $92.33 and a fifty-two week high of $157.50.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The company had revenue of $280.50 million during the quarter, compared to analysts’ expectations of $246.10 million. During the same period last year, the company posted ($0.30) earnings per share. The business’s revenue for the quarter was up 52.1% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 0.81 EPS for the current fiscal year.
Several research firms have commented on DXCM. BidaskClub cut shares of YY from a “sell” rating to a “strong sell” rating in a research note on Tuesday. BMO Capital Markets raised shares of TMAC Resources from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 2nd. TheStreet cut shares of The Providence Service from a “b-” rating to a “c+” rating in a research note on Friday, June 28th. ValuEngine raised shares of Xylem from a “hold” rating to a “buy” rating in a research note on Friday, June 21st. Finally, Raymond James reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Colfax in a research note on Thursday, May 2nd. Four analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $150.65.
In related news, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $115.73, for a total transaction of $694,380.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $116.92, for a total transaction of $46,768.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,065 shares of company stock valued at $8,207,313. Corporate insiders own 1.80% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: What does cost of debt say about a company’s financial health?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.